An expected surge in generic GLP-1s is anticipated to reshape not only pharmaceutical pricing and access but also the global MedTech ecosystem supporting drug delivery.
Akila Samiiya, Lead Analyst at Beroe and Rahul R Patil, Medzus, break down what the rise of generics means for drug delivery device procurement and what leaders should be doing about it now.
Related Reading
